Macrogen

Macrogen EBIT per Share

The EBIT per Share of Macrogen (038290.KQ) as of Oct 29, 2026 is 16.70 KRW. In the previous year, EBIT per Share was -842.00 KRW — a change of -101.98% (higher).

EBIT per Share

16.70KRW

YoY

-101.98%

Last updated:

EBIT per Share of Macrogen is 2025 16.70 KRW. EBIT per Share of Macrogen was 2024 -842.00 KRW. It decreases by -101.98% higher compared to the previous year.

The Macrogen EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
90.59 KRW
Jan 1, 2019
524.66 KRW
Jan 1, 2020
1,137.32 KRW
Jan 1, 2021
244.41 KRW
Jan 1, 2024
-842.00 KRW
Jan 1, 2025
16.70 KRW
Jan 1, 2026 (e)
1,446.08 KRW
Jan 1, 2027 (e)
2,958.69 KRW
The Macrogen EBIT per Share history
YEAREBIT per ShareYoY
est2,958.69KRW+104.60%
est1,446.08KRW+8,557.84%
16.70KRW-101.98%
-842.00KRW-444.50%
244.41KRW-78.51%
1,137.32KRW+116.77%
524.66KRW+479.16%
90.59KRW-62.40%
240.92KRW-54.42%
528.54KRW-38.12%
854.08KRW+162.74%
325.07KRW-27.11%
445.95KRW-31.23%
648.44KRW+5.06%
617.22KRW+107.56%
297.38KRW-329.19%
-129.75KRW-166.11%
196.25KRW-245.91%
-134.50KRW-76.87%
-581.57KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Macrogen Stock analysis

What does Macrogen do? Macrogen Inc. generates revenue through its four business divisions. The DNA sequencing division provides genome sequencing analysis services to clients requiring genetic data processing. The DNA chips division sells products including Illumina chips, MacArray chips, and customized chips to research institutions and biotech firms. The transgenic and knockout mouse division offers gene engineering services to pharmaceutical companies and academic laboratories. The oligonucleotide DNA division supplies oligonucleotide DNA manufacturing services to biotechnology clients. All services are delivered domestically and internationally to established market segments. The company's DNA chips division markets specific branded products like Illumina chips and MacArray chips, which are purchased by research organizations and biotechnology enterprises. Gene engineering services from the transgenic division are bought by pharmaceutical companies seeking to develop new treatments. Oligonucleotide DNA manufacturing services target biotech clients needing specialized DNA synthesis. Domestic and overseas markets represent the primary customer segments for all divisions. Macrogen's product portfolio includes DNA sequencing services, DNA chip products, gene engineering solutions, and oligonucleotide DNA manufacturing. Clients include research institutions, pharmaceutical companies, academic laboratories, and biotechnology firms. The DNA chips division's branded products are specifically named in the description, while other services are described by their technical functions. Market segments are defined by the company's domestic and international operations. Macrogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Macrogen stock

EBIT per Share of Macrogen is 16.70 KRW in 2025.

EBIT per Share of Macrogen changed from -842.00 KRW to 16.70 KRW, representing a -101.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Macrogen since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Macrogen

All Key Metrics — Macrogen